Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

237 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The clinical impact of acquired von Willebrand syndrome secondary to Waldenström macroglobulinemia: an underrecognized source of major bleeding events.
Chohan KL, Pruthi RK, Zanwar S, Paludo J, Go R, Pardanani A, Ashrani A, Cook JM, Thompson CA, Chanan-Khan A, Ailawadhi S, Habermann TM, Witzig TE, Gertz MA, Dingli D, Buadi FK, Dispenzieri A, Leung N, Kumar SK, Rajkumar V, Nichols WL, Kyle RA, Ansell SM, Kapoor P, Sridharan M, Abeykoon JP. Chohan KL, et al. Among authors: chanan khan a. Leukemia. 2024 Nov;38(11):2497-2500. doi: 10.1038/s41375-024-02393-6. Epub 2024 Aug 28. Leukemia. 2024. PMID: 39198620 No abstract available.
MicroRNA and long non-coding RNA analysis in IgM-monoclonal gammopathies reveals epigenetic influence on cellular functions and oncogenesis.
Chohan K, Paludo J, Dasari S, Mondello P, Novak JP, Abeykoon JP, Wenzl K, Yang ZZ, Jalali S, Krull JE, Braggio E, Manske MK, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan A, Kapoor P, Kyle RA, Gertz MA, Novak AJ, Ansell SM. Chohan K, et al. Among authors: chanan khan a. Haematologica. 2024 May 1;109(5):1570-1575. doi: 10.3324/haematol.2023.283927. Haematologica. 2024. PMID: 38058213 Free PMC article. No abstract available.
Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma.
Parrondo RD, LaPlant BR, Elliott J, Fernandez A, Flott CJ, Arrington D, Chapin D, Brown J, Das S, Roy V, Chanan-Khan AA, Ailawadhi S. Parrondo RD, et al. Among authors: chanan khan aa. Blood Cancer J. 2024 Sep 5;14(1):152. doi: 10.1038/s41408-024-01134-3. Blood Cancer J. 2024. PMID: 39237502 Free PMC article. Clinical Trial. No abstract available.
Multiomics analysis of IgM monoclonal gammopathies reveals epigenetic influence on oncogenesis via DNA methylation.
Chohan K, Paludo J, Dasari S, Mondello P, Novak JP, Abeykoon JP, Wenzl K, Yang ZZ, Jalali S, Bhardwaj V, Krull JE, Braggio E, Manske MK, Paulus A, Reeder CB, Ailawadhi S, Chanan-Khan A, Kapoor P, Kyle RA, Gertz MA, Novak AJ, Ansell SM. Chohan K, et al. Among authors: chanan khan a. Blood. 2024 Sep 19;144(12):1284-1289. doi: 10.1182/blood.2023023639. Blood. 2024. PMID: 38968152
Factors determining utilization of stem cell transplant for initial therapy of multiple myeloma by patient race: exploring intra-racial healthcare disparities.
Ailawadhi S, Adu Y, Frank RD, Das S, Hodge DO, Fernandez A, Flott C, Elliott J, Parrondo R, Sher T, Roy V, Chanan-Khan AA. Ailawadhi S, et al. Among authors: chanan khan aa. Blood Cancer J. 2024 May 28;14(1):86. doi: 10.1038/s41408-024-01067-x. Blood Cancer J. 2024. PMID: 38806475 Free PMC article.
A phase II study of ibrutinib in combination with ixazomib in patients with Waldenström macroglobulinaemia.
Parrondo RD, Dutta N, LaPlant BR, Elliott J, Fernandez A, Zimmerman A, Cicco G, Han B, Heslop K, Chapin D, Sher T, Roy V, Rasheed A, Das S, Chanan-Khan AA, Paulus A, Ailawadhi S. Parrondo RD, et al. Among authors: chanan khan aa. Br J Haematol. 2024 May;204(5):1825-1829. doi: 10.1111/bjh.19320. Epub 2024 Jan 29. Br J Haematol. 2024. PMID: 38286472 Clinical Trial.
Detailed safety profile of acalabrutinib vs ibrutinib in previously treated chronic lymphocytic leukemia in the ELEVATE-RR trial.
Seymour JF, Byrd JC, Ghia P, Kater AP, Chanan-Khan A, Furman RR, O'Brien S, Brown JR, Munir T, Mato A, Stilgenbauer S, Bajwa N, Miranda P, Higgins K, John E, de Borja M, Jurczak W, Woyach JA. Seymour JF, et al. Among authors: chanan khan a. Blood. 2023 Aug 24;142(8):687-699. doi: 10.1182/blood.2022018818. Blood. 2023. PMID: 37390310 Free PMC article. Clinical Trial.
Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
Ailawadhi S, Chen Z, Huang B, Paulus A, Collins MC, Fu LT, Li M, Ahmad M, Men L, Wang H, Davids MS, Liang E, Mekala DJ, He Z, Lasica M, Yannakou CK, Parrondo R, Glass L, Yang D, Chanan-Khan A, Zhai Y. Ailawadhi S, et al. Among authors: chanan khan a. Clin Cancer Res. 2023 Jul 5;29(13):2385-2393. doi: 10.1158/1078-0432.CCR-22-3321. Clin Cancer Res. 2023. PMID: 37074726 Free PMC article.
Daratumumab-lenalidomide and daratumumab-pomalidomide in relapsed lenalidomide-exposed or refractory multiple myeloma.
Alhaj Moustafa M, Parrondo R, Abdulazeez MF, Roy V, Sher T, Alegria VR, Warsame RM, Fonseca R, Rasheed A, Gonsalves WI, Kourelis T, Kapoor P, Buadi FK, Dingli D, Hayman SR, Reeder CB, Chanan-Khan AA, Ailawadhi S. Alhaj Moustafa M, et al. Among authors: chanan khan aa. Anticancer Drugs. 2024 Jan 1;35(1):63-69. doi: 10.1097/CAD.0000000000001520. Epub 2023 Apr 6. Anticancer Drugs. 2024. PMID: 37067996
237 results